Celgene — Merger or Acquisition (March 2019)
107 slides from Celgene's merger presentation, Mar 19, 2019
Slide 1: Transaction Update Investor Presentation
Transaction Update INVESTOR PRESENTATIONMARCH 19, 2019
Slide 2: Important Information For Investors And Stockholders
Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securiti
Slide 3: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking StatementsThis communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking
Slide 4: The Celgene Acquisition: A Financially and Strategically Compelling Transaction
The Celgene Acquisition: A Financially and Strategically Compelling Transaction >40% ~10% ~11% $2.5Bn Free cash flow in first three years Credit rating provides future flexibility Accretion to EPS in first full year (and accretive every year through 2025) Accretive to DCF value per share IRR, well a
Slide 5: We Expect to Create Significant Value
We Expect to Create Significant Value More than 80% of transaction cost supported by value of currently marketed products and synergiesValue of currently marketed products reflects more conservative assumptions than Street analyst consensus, primarily driven by RevlimidStreet estimates for currently
Slide 6: Analysis Based on Conservative, Risk-Adjusted Projections for Celgene
Analysis, Including DCF, Based on Conservative, Risk-Adjusted Projections for Celgene Source: Capital IQ, SEC filingsCapital IQ median as of 01/02/2019 Consensus1 Celgene Blended Mgmt. Case BMS Projections for Celgene Conducted extensive due diligence on Revlimid IP estateModeled base commercial ass
Slide 7: Positive Revlimid Patent Decisions Further De-Risk Our Forecast
Positive Revlimid Patent Decisions Post-Announcement Further De-Risk Our Forecast Recent US Patent and Trademark Office (USPTO) decisions declining to institute inter partes reviews (IPRs) challenges on Revlimid patents further de-risks our Revlimid forecastOn February 11, 2019, the USPTO denied req
Slide 8: Celgene Provides a 'String-of-Pearls' at an Attractive Valuation
Celgene Provides a ‘String-of-Pearls’ in One Transaction and at an Attractive Valuation Traditional ‘string-of-pearls’ strategy difficult, longer to execute and requires significant premiumsRequires successfully identifying and winning multiple potentially competitive processesStreet estimates for C
Slide 9: Near-Term Performance Relatively De-Risked
Near-Term Performance Relatively De-Risked Combined company growth to be driven by existing key market-leading franchisesConservative BMS forecast for Celgene below Street consensus and Celgene management projectionsCelgene’s “Big 5” near-term launches significantly de-risked Combined portfolio of >
Slide 10: The Acquired Portfolio Strengthens Our Strategic Position
The Acquired Portfolio Strengthens Our Strategic Position Bolsters Leading Franchises and Pipeline #1 in oncology; #1 in cardiovascular; Top 5 in immunology and inflammationPremier commercial hematology business9 current products > $1Bn in annual salesAdds “Big 5” pipeline of first-in-class or best-
Slide 11: Opportunistic Timing Resulted in Attractive Purchase Price
Opportunistic Timing Resulted in Attractive Purchase Price And Our Offer Price Was Lower Than Analyst Price Targets for Celgene 6.7x Celgene NTM P/E 1 Source: Capital IQConsensus estimate; not burdened by stock-based compensationExcludes CVR valueDefined as Celgene stock price divided by Bristol-Mye
Slide 12: Analysts Have Endorsed Both The Strategy and The Value
Analysts Have Endorsed Both The Strategy and The Value “Beyond the lack of alternatives that could provide a similar level of upside to the proposed deal (we note that the opposing shareholders have not come forward with any sort of concrete Plan B, with no over-the-top bidders in sight), we think t
Slide 13: Strong operating performance drives long-term value creation
Strong operating performance drives long-term value creationWhile we are not satisfied with recent share price performance, largely driven by dynamics in first-line lung cancer, the BMS team has generated a track-record of strong operating and financial results: 5-year CAGRs for net revenue and adju
Slide 14: We Have a Strong Track Record of Financial Results
Net Sales, $Bn We Have a Strong Track Record of Financial Results… $16.4 $15.9 $16.6 $19.4 $20.8 $22.6 CAGR6.6% Adj. Operating Income1, $Bn CAGR13.1% Adj. Operating Margin1 % Adj. EPS +725bps 21.1% 21.8% 23.4% 25.9% 25.0% 28.3% $3.5 $3.5 $3.9 $5.0 $5.2 $6.4 $1.82 $1.85 $2.01 $2.83 $3.01 $3.98 CAGR16
Slide 15: With a High Degree of Execution Consistency
…With a High Degree of Execution Consistency Adjusted EPS Results Have Beat or Met Consensus Expectations in 92% of Quarters Since the Beginning of 2013 (22/24 Quarters)1 Quarterly EPS ($ / share); 1Q 2013 – 4Q 2018 Sales Have Beat or Met Consensus Exp
Slide 16: Opdivo's Commercial Success Demonstrates Our Ability to Maximize Pipeline Value
Opdivo’s Commercial Success Demonstrates Our Ability to Maximize the Value of Our Pipeline Top Oncology Products: Cumulative Sales in 4 Years Post Launch US Sales ($Bn) Approvals Post-Launch 0 2 4 6 8 10 Opdivo Avastin Taxotere 12 14 16 in Yearsin the U.S. Approvals 16 4 Source: IQVIA NSP $ Sales US
Slide 17: BMS Share Price Since Opdivo Initial FDA Approval
BMS Share Price Since Opdivo Initial FDA Approval in Melanoma Share Price Volatility Driven By 1L Lung, Despite Strong Operating Performance and Success of Opdivo Franchise Share Price ($) Source: Thomson, Company Filings, Capital IQ Prior to August 5, 2016, we outperformed peers over 1-, 3-, and 5-
Slide 18: Opdivo's Future Growth Potential
Opdivo’s Future Growth Potential is Driven By:Broadened first line lung cancer programMultiple registered trials in various tumor typesIndustry leading development program in the adjuvant setting Lung 2L Leadership with 28% BMS I-O share3L+ SCLC Leadership with 68% BMS I-O share Melanoma 1L Leadersh
Slide 19: Our R&D Productivity is Strong
Our R&D Productivity is Strong P31: add point on new head/talent and capabilities in translational medicine as pipeline evolves Non-GAAP R&D spend per US Approval of a new molecular entity or new indication for an already approved product | Sources include Company Financial Reports, Drugs@FDA and BI
Slide 20: We Have Successfully Developed Our Portfolio Through Internal Investment and Acquisitions
Products sourced through acquisitionof for ~$2Bn1 $6.7Bn $1.3Bn $2.7Bn $2.0Bn We Have Successfully Developed Our PortfolioThrough Both Internal Investment and Acquisitions The Celgene acquisition continues our balanced approach to delivering new medicines INTERNAL EXTERNAL 2018 Sales: 2018 Sales: $6
Slide 21: Comprehensive process, thorough Board oversight, extensive diligence
Comprehensive process Prioritized more than 20 transformational and ‘string-of-pearls’ opportunitiesCelgene selected as most attractive opportunityThorough Board oversight Consistent Board involvement throughout process8 meetings to discuss Celgene opportunity, in addition to review by the Board’s S
Slide 22: A Robust Strategic Review Led Us To This Transaction
7 companies prioritized for deep dive analysis based on additional financial and strategic criteriaIncluded both transformational and 'string-of-pearls' 77 biopharma opportunities identified;22 prioritized for assessment based on strategic fit Celgene identified as lead opportunity based on strategi
Slide 23: We Considered Other Alternatives; Celgene Was the Best Value Creation Opportunity
We Considered Other Alternatives;Celgene Was By Far the Best Value Creation Opportunity ‘String-of-Pearls’ Acquisitions Value: Requires more significant premiumsMedian premium was 91% for $2-20Bn deals in the sector since 2018Timing: Would take longer to executeRisk: Requires winning multiple potent
Slide 24: We Mitigated Potential Risks At Multiple Points
We Mitigated Potential Risks At Multiple Points We Involved an Experienced Board at All Stages of the ProcessBoard consistently involved throughout strategic process; 8 meetings to discuss Celgene opportunity aloneBoard Integration Committee will oversee all aspects of merger integrationWe Used Cons
Slide 25: Our Robust Post-NDA Diligence Process Was Consistent With Precedent Transactions
Our Robust Post-NDA Diligence Process Was Consistent With Precedent Transactions NDA Signed IP Diligence Begins Management Presentation 11/23/18 41 days prior to announcement 11/28/18 36 days prior to announcement 12/13/18 21 days prior to announcement All Completed Acquisitions of Public Biopharma
Slide 26: The Transaction Was Overseen By An Experienced Board Of Directors
The Transaction Was Overseen By An Experienced Board Of Directors Which Has Delivered Significant Value Experienced, Fit-for-Purpose Board Independent, refreshed and effective10 / 11 directors independent (91%)Strong Lead Independent Director with robust responsibilities and oversightAdded 5 new dir
Slide 27: Our Revised Compensation Program To Drive Successful Execution
Our Revised Compensation Program To Drive Successful Execution and Value Creation Short-Term Annual incentive plan will include assessment of key integration execution metrics:Near-term pipeline delivery milestonesHuman capital managementSynergy savingsIntegration metrics will be a core component of
Slide 28: A Financially and Strategically Compelling Transaction
A Financially and Strategically Compelling Transaction >40% ~10% ~11% $2.5Bn Free cash flow in first three years Credit rating provides future flexibility Accretion to EPS in first full year (and accretive every year through 2025) Accretive to DCF per share IRR, well above ~8% Cost of Capital Run-ra
Slide 29: Appendices
Appendices: Appendix A: Supporting InformationAppendix B: The “Big 5” OpportunityAppendix C: Our March 6, 2019 Investor Presentation
Slide 30: Appendix A: Supporting Information
Appendix ASupporting Information
Slide 31: Opportunistic Timing for Celgene Acquisition
October 8, 2018: Positive Phase 3 STYLE study of Otezla in scalp psoriasisOctober 23, 2018: Positive results from Revlimid study in smoldering multiple myeloma October 25, 2018: Strong 3Q18 earnings; including a beat on revenue and EPSDecember 1/2, 2018: Positive luspatercept Phase 3 results at the
Slide 32: Comparable Large Acquisitions Have Created Long-Term Value
Comparable Large Acquisitions Have Created Long-Term Value Initial share price reactions are not indicative of long-term performanceMore near-term blockbuster products than prior large pharma transactionsLowest P/E multiple paid in large pharma transactions Terms Announcement Date January 3, 2019 Ma
Slide 33: Acquiring a Comparable Pipeline Would Be Unachievable via Public Biotech Targets
Acquiring a Pipeline Comparable to Celgene’s at the Price We Are Paying Would Be Unachievable via Public Biotech Targets Based on focused on biopharma entities with main equity listing in US; excludes companies with >$50Bn aggregate valueMarket data as of 3/14/2019; enterprise values based on Capita
Slide 34: Actions Taken Post CheckMate-026 Further Strengthen Our R&D Capabilities
Tom Lynch (preeminent lung cancer expert and former Chairman/CEO of Massachusetts General Physicians Organization) to enhance our R&D leadershipSaurabh Saha (ex-Delinia CEO, ex-Atlas Venture partner) to strengthen our Translational Medicine capabilitiesKate Owen (clinical trial expert at Novo Nordis
Slide 35: BMS Clinical Trial Outlook
BMS Clinical Trial Outlook 31 ONGOING REGISTRATIONAL PROGRAMS 34 REGIS. & PoC TRIALS PLANNED in 20191 30+ KEY DATA READOUTS (2019 – 2023)1 REGISTRATIONAL ONCOLOGY TRIALS EARLY ONCOLOGY PIPELINE INNOVATIVE MEDICINES 25+ trials in 15 tumor types reading out 2019 – 2023 (20+ trials in 10 priority tumor
Slide 36: Comprehensive Program Targeting First-Line Lung Cancer
P31: add point on new head/talent and capabilities in translational medicine as pipeline evolves Trial Expected Timing Rationale CM-227(Part 1a) 1H 2019 Opdivo + Yervoy or Opdivo monotherapy vs. chemotherapyTests hypothesis that IO can bring benefit to patients and eliminate chemotherapy as a standa
Slide 37: Our Compensation Program Has Evolved to Support Our Biopharma Strategy
During CEO’s Tenure, Our Compensation Program Has Evolved to Support Our Biopharma Strategy and Align With Shareholders Historical Program Design 2016 Program Enhancements Metrics: EPS (50%), Revenue (25%) and Pipeline (25%)Individual Performance Factor: Rewards results and behaviorsMax bonus payout
Slide 38: Appendix B: The "Big 5" Opportunity
Appendix BThe “Big 5” Opportunity
Slide 39: Why Are the Big 5 a Powerful Opportunity?
Why Are the Big 5 Such a Powerful Opportunity? Innovative ProgramsAll 5 are First-in-Class or potentially Best-in-ClassNear Term ApprovalsExpected launches in 2019 and 2020De-risked Assets3 out of the Big 5 have completed Phase 3 / pivotal trials2 have been submitted for regulatory approvalCVR will
Slide 40: Five Near-Term Product Launch Opportunities
Five Near-Term Product Launch Opportunities luspatercept liso-cel (JCAR017) bb2121 fedratinib ozanimod Description CVR Near-Term Milestones / De-Risking Events Best-in-Class selective S1P in relapsing forms of MS and First-in-Class in Inflammatory Bowel Disease First- and Best-in-Class novel a
Slide 41: Ozanimod Overview
Convenient oral option to treat patients with Multiple Sclerosis (MS) in a ~$23Bn segmentStrong efficacy profile and differentiated safety profile shown in two positive pivotal trialsRelapsing-Remitting Multiple Sclerosis (RRMS) filed in EU and on track to refile in U.S. 1Q 2019First-in-Class in Inf
Slide 42: Strong Efficacy and Potentially Best-in-Class Safety Profile
Source: FDA labels, clinicaltrials.gov Note: Cross Trial ComparisonAvonex ARR from Ozanimod Phase 3 clinical trial, Rebif ARR from Ocrevus Phase 3 clinical trialAnnualized relapse rate (ARR) Oral IV Subcutaneous / intramuscular1 Strong Efficacy Profile and Potentially Best-in-Class Safety Profile De
Slide 43: Significant Opportunity For Safer High-Efficacy Orals in RRMS
RRMS is a large patient population with need for efficacious and safe optionsPatients have a strong desire for high-efficacy oral medications with improved safety profileOrals comprise 45% of total salesGilenya (S1P) revenues annualizing at ~$3.3BnOzanimod efficacy profile supports utilization in ea
Slide 44: Ozanimod in Inflammatory Bowel Diseases
Ozanimod (1.0 mg) Placebo Ozanimod (0.5 mg) Ozanimod in Inflammatory Bowel Diseases (IBD): Strong Efficacy and Safety Across Key Endpoints Source: TOUCHSTONE Trial, a randomized double-blind, placebo-controlled study in 197 patients with ulcerative colitis. Sandborn et al., New England Journal of Me
Slide 45: Opportunity for First Approval Among S1Ps in IBD
Opportunity for First Approval Among S1Ps in IBD 1.5 0.5 0.0 1.0 Disease fully controlled Patients who progress to advanced therapies (e.g., biologics, novel orals) Moderate to severe patients U.S. / EU5 addressable IBD patients (2018)Millions of patients ~1.2 ~0.5 ~0.2 IBD is a large patient popula
Slide 46: Regulatory Path and Clinical Program
RRMS filed in EU and on track to refile in U.S. 1Q 2019Ulcerative Colitis Phase 3 data expected to read out mid-2020Rationale supported by positive Phase 2 data in UC and CD (placebo-controlled and single-arm, respectively) Crohn’s diseases Phase 3 trial underwayEndoscopic clinical improvement seen
Slide 47: Luspatercept Overview
Novel approach to treating patients with anemia demonstrated by positive Phase 3 dataReduced transfusion burden and anemia in myelodysplastic syndromes (MDS)Greater proportion of transfusion burden reduction in beta thalassemiaRegulatory submissions expected for both indications in 1H 2019Potential
Slide 48: First-in-Class Anemia Treatment with Positive Phase 3 Data in MDS
First-in-Class Anemia Treatment with Positive Phase 3 Data in Myelodysplastic Syndromes (MDS) Source: ClinicalTrials.gov, Fenaux et al., ASH (2018), Platzbecker et al., Lancet Oncology (2017), Bajar et al., Blood (2014), Celgene websiteNotes: 1. mHI-E (modified erythroid response): defined as a hemo
Slide 49: Opportunity to Lower Transfusion Burden in MDS
High unmet need with limited options~90K low-intermediate risk MDS patients with anemia (U.S. and EU5)~90% of patients receive a transfusion and majority become transfusion dependentAlthough erythroid stimulating agents (ESAs) are frequently used, they have significant limitationsApproximately two-t
Slide 50: Luspatercept Reduced Transfusion Dependence in Beta Thalassemia
Luspatercept Demonstrated Reduced Transfusion Dependence in Patients with Beta Thalassemia (BT) 21.4%(n = 48) Luspatercept(n = 224) Placebo(n = 112) 4.5%(n = 5) Patients Achieving ≥ 33% Transfusion Burden Reduction (%) Source: Celgene investor materialsNote: The BELIEVE trial studied adult patients
Slide 51: Regulatory Path and Clinical Programs in Earlier Lines
Initial 2L MDS (RS+) and transfusion-dependent BT filing expected in 1H2019Ongoing Phase 3 label expansion trials: 1L MDS regardless of RS status vs. epoetin-alfaNon-transfusion-dependent BTAdditional life-cycle opportunities in myelofibrosis and other chronic anemias Regulatory Path and Clinical Pr
Slide 52: Industry Leading CAR-T Portfolio Supported by Oncology Commercial Capabilities
Industry Leading CAR-T Portfolio Supported by Leading Oncology Commercial Capabilities CURRENT CAR-T OPPORTUNITY LIMITED BY: BMS and CELGENE CAR-T OPPORTUNITY ENABLED BY: THERAPEUTIC PROFILE (SAFETY) MARKET ACCESS & REIMBURSEMENT COMPLEX MANUFACTURING & LOGISTICS LIMITED TO LATE LINE THERAPY Potenti
Slide 53: Liso-cel Overview
Potential Best-in-Class CAR-T for B Cell malignancies including Diffuse large B cell lymphoma (DLBCL) and Chronic lymphocytic leukemia (CLL)Strong efficacy with 46% complete response ratesPotential superior safety profile with low 1% CRS rateRegulatory submission expected in 2H 2019 in relapsed/refr
Slide 54: Strong Efficacy Profile with Improved Complete Response Rates
Strong Efficacy Profile with Significantly Improved Complete Response Rates Relative to Standard of Care EFFICACYResponse Rate at 6 months SAFETYCytokine Release Syndrome ™ ™ ™ ™ Neurotoxicity ™ ™ U.S. submission expected 2H2019 Data presented to show potential profile of Liso-cel, which is subject
Slide 55: Opportunity to Improve Outcomes in DLBCL
Opportunity to Improve Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Source: DRG, EvaluatePharma ~22K relapsed/refractory patients treated per year (U.S. and EU5) Significant unmet exists for relapsed/refractory patients Poor efficacy of historical therapies; ORR <40% and CR <20% mOS is 6-7 mont
Slide 56: Impressive CLL Data in Heavily Pre-Treated Population
Impressive CLL Data in Heavily Pre-Treated Population Suggests a Potential New Standard 44% 4% Liso-cel results in relapsed/refractory CLL (Response rate) 8% Bendamustine-Rituximab(N=195) 84% Venetoclax-Rituximab(N=194) 38% Liso-cel(N=16) PR CR Phase III MURANO Study Phase I/II TRANSCEND CLL Median
Slide 57: Broad Clinical Development Plan for Liso-cel
Broad Clinical Development Plan to Advance Liso-cel into Earlier Lines and Additional Indications Transcend NHL 001 (Ph I 3L + R/R) Transcend World (Ph II 3L + R/R EU and Japan; 2L R/R transplant ineligible) Transform (Ph III 2L R/R transplant eligible) Pilot (Ph II 2L R/R transplant ineligible) Tra
Slide 58: bb2121 Overview
First- and Potential Best-in-Class BCMA CAR-TTransformational efficacy in highly refractory multiple myeloma (MM)Complete response rates of ~50% in RRMMRegulatory submission expected in late 2019 / early 2020 Robust development plan with the potential to expand into earlier lines of therapy 2L and 3
Slide 59: 50% Complete Response Rate in Multiple Myeloma Patients
Transformational Efficacy, Demonstrating a 50% Complete Response Rate in Multiple Myeloma Patients U.S. submission expected in late 2019/early 2020 Standard Treatment Regimens Across Multiple Myeloma (%) Emerging bb2121 Profile ORR 69%-82% ORR 59%-91% ORR 29% - 59% ORR 96% N= 22 Complete Response PR
Slide 60: Opportunity to Further Transform Multiple Myeloma
~260K patients today and expected to reach ~$25Bn + in sales by 2022Patient prevalence in 3L and 4L of ~47KSignificant unmet need for efficacy in relapsed/refractory patients Median overall survival is less than 12 monthsPotential to target high risk patients in earlier lines (2L+)15-20% of patients
Slide 61: Robust Clinical Program with Potential to Advance into Earlier Lines
Robust Clinical Program with the Potential to Advance into Earlier Lines PHASE 1 PHASE 2 PIVOTAL Ongoing Development in Multiple Myeloma 1L phase 2 studies 2L phase 2 initiated 3L+ phase 3 initiated 4L+ pivotal trial fully enrolled Planning for 2019 KarMMa™2 (MM-002) KarMMa™3 (MM-003) KarMMa™ (MM-00
Slide 62: Fedratinib Overview
Selective JAK2 inhibitor, potential oral alternative to current standard of care for patients with MyelofibrosisHigh unmet need in patients who are intolerant or relapsed from JakafiAccepted for Priority Review by FDA, PDUFA date of September 3, 2019Potential to address a broader patient population
Slide 63: First-in-Class Therapy Under FDA Review for Jakafi-Resistant Patients
High unmet medical need in MF patients that fail or cannot tolerate Jakafi EFFICACY (JAKARTA2 Trial) 55% of patients achieved splenic volume reduction of ≥35% compared to baseline at week 24 26% of patients achieved total symptom score ≥50% compared to baseline at week 24 Fedratinib: selective JAK2
Slide 64: Appendix C: Our March 6, 2019 Presentation
Appendix C Our March 6, 2019 Investor Presentation
Slide 65: Executive Summary
Executive Summary The Celgene acquisition has clear strategic rationale and represents a compelling value propositionEnhanced product leadership and pipeline: Combined company will be #1 in oncology, top 5 in immunology and inflammation, #1 in cardiovascular; 9 products over $1Bn in annual sales; 6
Slide 66: The Celgene Acquisition Has Clear Strategic Rationale
The Celgene Acquisition Has Clear Strategic Rationale and Represents a Compelling Value Proposition
Slide 67: Consistent with our strategy of delivering value for shareholders
Consistent with our strategy of delivering value for shareholders by enhancing core franchises and delivering innovative therapies for patientsCelgene pipeline includes 5 differentiated late-stage assets with low clinical risk, expected near-term approvals and incremental value creationExpanded earl
Slide 68: Strengthened Position in Both the Near- and Long-Term
Creates new company with increased scale while maintaining focus and agilityCreates leading Oncology company and adds a premier commercial hematology businessImmunology & Inflammation franchise with greater commercial scale and pipeline depthStronger combined company to address eventual loss-of-excl
Slide 69: Celgene Provides Late Stage Products With Near-Term Approvals
Celgene Provides 5 Late Stage Products With Near-Term Approvals and Relatively Low Clinical RiskBMS Projected Total Sales from “Big 5” in 2025 Consistent with Street Forecasts Ph 3 / PivotalComplete CVR Tied to Near Term Approval Key Benefits Current Status First- and Best-in-class novel anemia dr
Slide 70: Celgene Offers Leading Capabilities in Cell Therapy
Celgene Offers Leading Capabilities in Cell Therapy and 2 Differentiated Late-Stage CAR-T AssetsTransformational Modality with Unprecedented Efficacy Cell therapy market expected to grow from ~$1Bn in 2019 to >$15Bn in 2024¹Growing expectations for cell therapy given superior efficacy, expected evol
Slide 71: Liso-cel: Potential Best-in-Class anti-CD19 CAR-T
CLL Liso-celPotential Best-in-Class anti-CD19 CAR-T for B Cell Malignancies Broad Clinical Development Plan to Advance into Earlier Lines and Additional Indications PIVOTAL PHASE II PHASE I TRANSCEND WORLD (Ph II 3L+ R/R EU and Japan; 2L R/R transplant ineligible) DLBCL PLATFORM (Ph I/II 3L+ R/R com
Slide 72: bb2121 Anti-BCMA CAR-T in Late Line RRMM
bb2121 Anti-BCMA CAR-T with Transformational Efficacy in Late Line RRMM Potential U.S. Approval 2H 2020 Standard Treatment Regimens Across Multiple Myeloma (%) Emerging bb2121 Profile ORR 69%-82% ORR 59%-91% ORR 29% - 59% ORR 96% N= 22 Complete Response VGPR PR PIVOTAL PHASE II PHASE I Phase II stud
Slide 73: Significantly Expanded Early Stage Pipeline and New Technology Platforms
Celgene Provides a Significantly Expanded Early Stage Pipeline and New Technology Platforms Transaction provides BMS with >20 Phase 1 and 2 programsNew capabilities in cell therapy and protein homeostasisStrongest position in BCMA: 5 programs total, first expected BCMA launch product (bb2121), and 3
Slide 74: Significant Value Creation Opportunity From Celgene Pipeline
Significant Value Creation Opportunity From Celgene Pipeline More than 80% of transaction value supported by currently marketed products and synergies aloneValue of currently marketed products reflects Revlimid assumptions which are more conservative than those of sell-side analystsImplied cost of “
Slide 75: Celgene Provides a 'String-of-Pearls' at an Attractive Valuation
Celgene Provides a ‘String-of-Pearls’ in One Transaction and at an Attractive Valuation Traditional ‘string-of-pearls’ strategy difficult, longer to execute and at significant premiumsRequires successfully identifying and winning multiple potentially competitive processesStreet estimates for Celgene
Slide 76: Analysis Based on Conservative, Risk-Adjusted Projections for Celgene
Analysis Based on Conservative, Risk-Adjusted Projections for Celgene Source: Capital IQ, SEC filingsCapital IQ median as of 01/02/2019 Consensus1 Celgene Blended Mgmt. Case BMS Projections for Celgene Extensive due diligence conducted on Revlimid IP estateBMS base commercial assumptions below both
Slide 77: Significant Near-Term Free Cash Flow Generation
Significant Near-Term Free Cash Flow Generation 2020E – 2023E Pro Forma BMS + Celgene Cumulative Free Cash Flow In $Bn Source: SEC filings Transaction significantly enhances cash flow generation, enabling rapid deleveraging and providing flexibility for continued business development and return of c
Slide 78: ~$2.5Bn of Cost Synergies Provide for Over $20Bn in Value
~$2.5Bn of Cost Synergies Provide for Over $20Bn in Value Sources of Synergies % of Total Synergies Source: SEC Filings Overview of SynergiesSynergies represent $2.5Bn in sustainable long-term cost savings Represents ~13% of combined company OpEx; Well within biopharma precedents To be generated fro
Slide 79: BMS Equity Issued at Favorable Relative Valuation
BMS Equity Issued at Favorable Relative Valuation, Creating Value for BMS Shareholders 1.3x 1.8x BMS / Celgene Natural Exchange Ratio at Two-Year Lows1 January 1, 2017 to January 2, 2019 Opportunistic timing given favorable relative valuation of BMS versus Celgene equity Source: Capital IQ, SEC Fili
Slide 80: Highly Attractive Purchase Price
Highly Attractive Purchase Price Pre-Announcement Celgene Analyst Price Targets Higher than Offer PriceSeptember 3, 2018 to January 2, 2019 6.7x Celgene NTM P/E 1 Source: Capital IQConsensus estimate; not burdened by stock-based compensationExcludes CVR valueTransaction was withdrawnBased on final p
Slide 81: Combined Company to Grow Revenues in Each Year Through 2025
Combined Company to Grow Revenues in Each Year Through 2025 Pro Forma Revenue are pro forma for the transaction and for 2019 are based on full year contribution for purposes of comparison. These figures are based on numerous assumptions and estimates, including information provided to the Company by
Slide 82: Significantly Expanded Earnings Power of Combined Company
Significantly Expanded Earnings Power of Combined Company Source: SEC filings BMS Pro Forma Net Income BMS Standalone Net Income Transaction more than 40% accretive to EPS in first full yearAccretive to EPS in all years though 2025Significant free cash flow from combination to provide flexibility fo
Slide 83: Celgene Enhances Overall Business Profile of BMS
Celgene Enhances Overall Business Profile of BMS Meaningfully enhanced product diversification and margin profile Includes run-rate synergies of $2.5Bn Top 3 BMS Products as % of Standalone and Pro Forma Revenue 2025E Revenue Standalone vs. Pro Forma Margins 2018A Non-GAAP Operating Income Margin
Slide 84: BMS Has a Strong Track Record of Financial and Operational Outperformance
Bristol-Myers Squibb Has a Strong Track Record of Financial and Operational Outperformance
Slide 85: Robust Record of BMS Operating and Financial Performance
Robust Record of BMS Operating and Financial Performance While we are not satisfied with recent share price performance, largely driven by dynamics in first-line lung cancer, the Bristol-Myers Squibb team has generated a track-record of strong operating and financial results over the last five years
Slide 86: Our Strategic Foundation: Diversified Specialty BioPharma
Diversified Specialty BioPharma Best of BIOTECH Best of PHARMA INNOVATION Focused and Integrated The Best PEOPLE helping patients in their fight against serious disease Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a
Slide 87: Proven Success in Transitioning Portfolio Over Time
Proven Success in Transitioning Portfolio Over Time BMS Historical Total Sales ($Bn) Contribution of Sales (%) +$14Bn Established Brands Other Prioritized Brands Prioritized Brands Launched Since 2011 Other +$2Bn ($9Bn) +$6Bn Management has a proven track record of success in transitioning a mature
Slide 88: BMS Has Outperformed Peers Across Multiple Metrics
Revenue Growth 1 BMS Has Outperformed Peers Across Multiple Metrics Over Last 5 Years Adj. Operating Margin Improvement 1, 2 Adj. EPS Growth1 % CAGR Change in bps; 2013 - 2018 % CAGR 3 3 3 Sources: Company filings & Capital IQMetrics shown based on as adjusted reported financials; historical financi
Slide 89: Track Record of Portfolio Development Through Internal Investment and Acquisitions
Products sourced through acquisitionof for $1.8Bn $6.7B $1.3B $2.7B $2.0B Track Record of Portfolio Development Through Both Internal Investment and Acquisitions Celgene acquisition is an extension of historical balanced approach to delivering new medicines to patients INTERNAL EXTERNAL 2018 Sales:
Slide 90: Commercial Excellence Extends Across Multiple Strategic Objectives
Eliquis 3rd to enter the novel anticoagulant (NOAC) market in 2012Able to push to the leading position through solid execution and a differentiated clinical profile#1 NOAC$6.4Bn of Eliquis sales in 2018 showing 32% growth Successfully launched OpdivoDespite being 2nd to enter US anti PD-1 market at
Slide 91: I-O Commercial and Development Success
I-O Commercial and Development Success Top Oncology Products: Cumulative Sales in 4 Years Post Launch US Sales ($Bn) Approvals Post-Launch 0 2 4 6 8 10 Opdivo Avastin Taxotere 12 14 16 in Yearsin the U.S. Approvals 16 4 Source: IQVIA NSP $ Sales US only
Slide 92: BMS Continues to Lead in Key Tumors Where Opdivo is Approved
Lung 2L Leadership with 28% BMS I-O share3L+ SCLC Leadership with 68% BMS I-O share Melanoma 1L Leadership with 60% BMS I-O shareAdjuvant Leadership with 77% BMS I-O share Renal cell Carcinoma 1L Leadership with 44% BMS I-O share2L Leadership with 52% BMS I-O share Head & Neck Post platinum 18% BMS
Slide 93: Eliquis Has Become #1 NOAC Globally
Eliquis Annual Sales $Bn; 2013 - 2018 5 Year CAGR: +113% +430% +140% +80% +46% +32% Annual Growth: #1 NOAC(Mar’15) #1 OAC(Feb’16) Evolution of OAC Market Share in Atrial Fibrillation (AF)1 January 2013 – September 2018 Chart represents New-to-Brand (Naïve+Switch) Rxs (NBRx). Eliquis, Xarelto, Pradax
Slide 94: Commitment to Margin Expansion With Operating Model Transformation
Commitment to Margin Expansion With Ongoing Operating Model Transformation Company operating model transformation progress continues – originally announced 3Q 2016Significant operational changes have been successfully implemented while continuing to maintain favorable R&D productivity metrics and be
Slide 95: Strong Track Record of Financial Results
Net Sales, $Bn Strong Track Record of Financial Results… $16.4 $15.9 $16.6 $19.4 $20.8 $22.6 CAGR6.6% Adj. Operating Income1, $Bn CAGR13.1% Adj. Operating Margin1 % Adj. EPS +725bps 21.1% 21.8% 23.4% 25.9% 25.0% 28.3% $3.5 $3.5 $3.9 $5.0 $5.2 $6.4 $1.82 $1.85 $2.01 $2.83 $3.01 $3.98 CAGR16.9% Source
Slide 96: With a High Degree of Execution Consistency
…With a High Degree of Execution Consistency… Adjusted EPS Results Have Beat or Met Consensus Expectations in 92% of Quarters Since the Beginning of 2013 (22/24 Quarters)1 Quarterly EPS ($ / share); 1Q 2013 – 4Q 2018 Sales Have Beat or Met Consensus Ex
Slide 97: Sustained Growth in Key Global Franchises
Immuno-Oncology (Opdivo + Yervoy) Quarterly Sales Since the Beginning of 2013 Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018 Eliquis Quarterly Sales Since the Beginning of 2013 Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018 Y-o-Y Growth: Y-o-Y Growth: Source: Company Filings …And Sustained Growth in Key Global
Slide 98: Board and Management Conducted a Robust Process and Are Committed to Integration
The Board and Management Team Conducted a Robust Process and Diligence and Are Committed to a Successful Integration
Slide 99: BMS regular process to evaluate strategic opportunities
BMS has a regular process to actively evaluate strategic opportunities to create long-term value for shareholdersPrioritized more than 20 opportunities in early 2018, and narrowed down over time to focus on the 7 best opportunitiesOpportunities included 'string-of-pearls' strategies as well as other
Slide 100: The Celgene Acquisition Resulted From a Robust Strategic Review
7 companies prioritized for deep dive analysis based on additional financial and strategic criteriaIncluded both transformational and 'string-of-pearls' 77 biopharma opportunities identified;22 prioritized for assessment based on strategic fit Celgene identified as lead opportunity based on strategi
Slide 101: Robust Diligence Process on Celgene Opportunity
Robust Diligence Process on Celgene Opportunity Work led by ~25 BMS senior leaders and their teams across functional areas and supported by subject matter experts and financial and legal advisorsConducted assessment of markets and drivers of key assets and indications based on competitive intel, pri
Slide 102: Revlimid IP Was a Key Focus of Due Diligence
Revlimid IP Was a Key Focus of Due Diligence BMS and its legal advisors conducted an extensive review of the entire Revlimid patent estateReceived access to this non-public information prior to the beginning of other confidential diligence Reviewed the non-public, unredacted Natco agreementExtensive
Slide 103: Post-NDA Diligence Process Consistent With Precedent Transactions
Post-NDA Diligence Process Consistent With Precedent Transactions NDA Signed IP Diligence Begins Management Presentation 11/23/18 41 days prior to announcement 11/28/18 36 days prior to announcement 12/13/18 21 days prior to announcement All Completed Acquisitions of Public Biopharma Companies Over
Slide 104: BMS is Focused and Committed to a Successful Integration
BMS is Focused and Committed to a Successful Integration Complementary nature of businessesNot a traditional big pharma, high-overlap dealStrong team in place to manage integrationTop priority of leadershipFull-time integration leads appointed for each company and for each functional areaExperienced
Slide 105: Complementary Organizations – Streamlined Integration Process
Complementary Organizations – Streamlined Integration Process BMS Celgene Commentary Source: Company filings and websitesBMS’s principal executive office per SEC filings is New York, NYPro forma for divestiture of 1,500 USPA employees; BMS reported 23,300 employees in its 2018 10KPro forma for dives
Slide 106: Board of Directors Experience
Director Director Since Experience Giovanni Caforio, M.D. 2014 Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Vicki L. Sato, Ph.D. 2006 Lead Independent Director, Bristol-Myers Squibb; Independent Chairman of the Board, Denali Therapeutics; Former Professor of Management Pra
Slide 107: Board and Governance – Relevant Experience and Accountability
Board and Governance – Relevant Experience and Accountability 10 / 11 directors independent (91%)Strong Lead Independent Director with robust responsibilities and oversight5 new independent directors added in the past 3 years1 Average tenure of 5.5 years vs. S&P average tenure of 8.1 yearsAnnually e